# Pharmacosmos A/S clinical trials: 36 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 36 trials with Pharmacosmos A/S as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Pharmacosmos A/S: 36 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/pharmacosmos-a-s

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 36
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 25 newest of 36, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 16, 2026 | NCT07473128 | Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer | Pharmacosmos A/S | Phase 3 | Recruiting | Limited Stage Small Cell Lung Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07473128) |
| April 16, 2025 | NCT06929806 | Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure | Pharmacosmos A/S | Phase 3 | Recruiting | Chronic Heart Failure, Iron Deficiencies | 1,900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06929806) |
| May 24, 2023 | NCT05874401 | Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan | Pharmacosmos A/S | Phase 4 | Active not recruiting | Extensive-stage Small-cell Lung Cancer | 302 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05874401) |
| January 23, 2023 | NCT05693909 | A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes | Pharmacosmos A/S | Phase 2 | Recruiting | Beta Thalassemia Major Anemia, Myelodysplastic Syndrome | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05693909) |
| September 19, 2022 | NCT05545202 | A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in... | Pharmacosmos A/S | Phase 4 | Unknown | Malignant Lymphoma, Multiple Myeloma | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05545202) |
| January 5, 2022 | NCT05179226 | Multi-center Trial of Ferric Derisomaltose in Children 0 to \<18 Years of Age With Iron Deficiency Anemia | Pharmacosmos A/S | Phase 3 | Recruiting | Iron Deficiency, Anaemia in Children | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05179226) |
| March 15, 2018 | NCT03466983 | A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects... | Pharmacosmos A/S | Phase 4 | Completed | IBD | 97 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03466983) |
| August 3, 2017 | NCT03238911 | Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron... | Pharmacosmos A/S | Phase 3 | Completed | Iron Deficiency Anaemia, Iron Deficiency Anemia | 123 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03238911) |
| August 2, 2017 | NCT03237065 | Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron... | Pharmacosmos A/S | Phase 3 | Completed | Iron Deficiency Anaemia, Iron Deficiency Anemia | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03237065) |
| June 15, 2017 | NCT03188445 | Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy. | Pharmacosmos A/S | Phase 4 | Completed | Iron Deficiency Anemia of Pregnancy | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03188445) |
| January 6, 2017 | NCT03013439 | Dose-escalation Trial of the Safety, Pharmacokinetics, and Pharmacodynamics of Iron Isomaltoside (Monofer®) | Pharmacosmos A/S | Phase 1 | Completed | Anemia, Deficiency Diseases, Anemia, Iron Deficiency, Hematologic Disease, Iron Metabolism Disorders | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03013439) |
| November 11, 2016 | NCT02962648 | An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®) | Pharmacosmos A/S | Phase 3 | Completed | Iron Deficiency Anemia, Iron Deficiency Anaemia | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02962648) |
| October 21, 2016 | NCT02940886 | Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA) | Pharmacosmos A/S | Phase 3 | Completed | Iron Deficiency Anaemia, Iron Deficiency Anemia | 1,512 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02940886) |
| October 21, 2016 | NCT02940860 | Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney... | Pharmacosmos A/S | Phase 3 | Completed | Iron Deficiency Anaemia, Iron Deficiency Anemia, Chronic Kidney Disease | 1,538 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02940860) |
| June 30, 2015 | NCT02484768 | IV Iron Treatment of Restless Legs Syndrome | Pharmacosmos A/S | Phase 2 | Withdrawn | Restless Legs Syndrome | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02484768) |
| November 25, 2014 | NCT02301026 | A Non-interventional Study of Diafer in Subjects With CKD on Haemodialysis for Treatment of Iron Deficiency | Pharmacosmos A/S | Observational | Completed | Anaemia in Chronic Kidney Disease | 209 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02301026) |
| June 24, 2014 | NCT02172001 | A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo | Pharmacosmos A/S | Phase 3 | Withdrawn | Iron Deficiency Anemia | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02172001) |
| May 2, 2014 | NCT02130063 | IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose | Pharmacosmos A/S | Phase 3 | Completed | Iron Deficiency Anaemia | 511 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02130063) |
| July 16, 2013 | NCT01900197 | Time to Relapse of Iron Deficiency Anemia After Standard Treatment With a New Intravenous Iron (Monofer®) | Pharmacosmos A/S | Observational | Completed | Iron Deficiency Anemia | 391 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01900197) |
| July 10, 2013 | NCT01895231 | A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Iron-deficient Blood Donors | Pharmacosmos A/S | Phase 3 | Completed | Iron-deficiency | 107 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01895231) |
| July 10, 2013 | NCT01895218 | Treatment of Women After Postpartum Haemorrhage | Pharmacosmos A/S | Phase 3 | Completed | Postpartum Haemorrhage | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01895218) |
| July 10, 2013 | NCT01895205 | Treatment of Women After Severe Postpartum Haemorrhage | Pharmacosmos A/S | Phase 3 | Completed | Severe Postpartum Haemorrhage | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01895205) |
| May 16, 2012 | NCT01599702 | Iron Isomaltoside 1000 (Monofer®) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease | Pharmacosmos A/S | Phase 3 | Completed | Inflammatory Bowel Disease | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01599702) |
| March 27, 2012 | NCT01563367 | A Prospective, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Non-Anaemic Patients... | Pharmacosmos A/S | Phase 3 | Completed | Non-anaemic Patients Undergoing Cardiac Surgery | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01563367) |
| November 10, 2011 | NCT01469078 | Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections in Subjects With Stage 5... | Pharmacosmos A/S | Phase 1 | Completed | Chronic Kidney Disease | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01469078) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 6 |
| Phase 2 | 2 |
| Phase 3 | 22 |
| Phase 4 | 4 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 28 |
| Recruiting | 4 |
| Withdrawn | 2 |
| Active not recruiting | 1 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Anemia, Iron-Deficiency | 13 |
| Iron Deficiencies | 8 |
| Renal Insufficiency, Chronic | 6 |
| Anemia | 6 |
| Inflammatory Bowel Diseases | 4 |
| Postpartum Hemorrhage | 2 |
| Neoplasms | 2 |
| Hypophosphatemia | 2 |
| Small Cell Lung Carcinoma | 1 |
| Disease | 1 |
| Lymphoma | 1 |
| Multiple Myeloma | 1 |
| Heart Failure | 1 |
| Deficiency Diseases | 1 |
| Hematologic Diseases | 1 |
| Iron Metabolism Disorders | 1 |
| Myelodysplastic Syndromes | 1 |
| Restless Legs Syndrome | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Concierge medicine practices in the United States](https://specstream.ai/data/businesses/concierge-medicine-practices/united-states)
- [Broadcast media production companies in the United States](https://specstream.ai/data/businesses/broadcast-media-production-companies/united-states)
- [B2B background check companies in the United States](https://specstream.ai/data/businesses/b2b-background-check-companies/united-states)
- [Wholesale grocers in the United States](https://specstream.ai/data/businesses/wholesale-grocers/united-states)
- [Tex-Mex restaurants in the United States](https://specstream.ai/data/businesses/tex-mex-restaurants/united-states)
- [Scientific laboratories in the United States](https://specstream.ai/data/businesses/scientific-laboratories/united-states)
